Hepatology
Hepatology (Baltimore, Md.) · ISSN 0270-9139
29
Publications in this journal
-
Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
-
Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study.
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.
-
Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
-
Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.
-
Noninvasive assessment of portal hypertension in patients with cirrhosis. Review
-
Combination of fibrosis tests: sequential or synchronous?
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
-
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
-
FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.
-
Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.
-
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.
-
The use of enzyme results for liver fibrosis evaluation neccessitates standardization.
-
Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C.
-
External validation of FibroIndex.
-
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
-
Diagnostic value of FibroTest with normal serum aminotransferases.
-
FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.
-
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.
-
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
-
A novel panel of blood markers to assess the degree of liver fibrosis.
-
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.
-
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
-
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
-
Noninvasive prediction of fibrosis in patients with chronic hepatitis C.
-
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.